Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis

Current therapies for treating antineutrophil cytoplasm autoantibody (ANCA) –associated vasculitis include cyclophosphamide and corticosteroids. Unfortunately, these agents are associated with severe adverse effects, despite inducing remission in most patients. Histone deacetylase inhibitors are effective in rodent models of inflammation and act synergistically with many pharmacological agents, including alkylating agents like cyclophosphamide. EDO-S101 is an alkylating fusion histone deacetylase inhibitor molecule combining the DNA alkylating effect of Bendamustine with a pan-histone deacetylase inhibitor, Vorinostat.

Source: Kidney International - August 26, 2018 Category: Urology & Nephrology Authors: Dearbhaile Dooley, Mirjan M. van Timmeren, Vincent P. O ’Reilly, Gareth Brady, Eóin C. O’Brien, Barbara Fazekas, Fionnuala B. Hickey, Emma Leacy, Charles D. Pusey, Frederick W.K. Tam, Thomas Mehrling, Peter Heeringa, Mark A. Little Tags: Basic Research Source Type: research